Surprisingly, p53 has been found to modulate ferroptosis by both the GPX4-dependent and GPX4-independent ferroptosis pathways, which suggests that targeting p53-mediated ferroptosis could be a potential treatment of chronic liver diseases, particularly HCC. The gene discussed is GPX4; the disease is hepatocellular carcinoma.